Menopause :: New data on hormone therapy must lead to re-evaluation of official guidelines

On World Menopause Day, the International Menopause Society calls upon health authorities to re-evaluate the new age-related data on hormone therapy and review their recommendations accordingly, with an emphasis on women below 60, for whom the safety profile of HT is favorable and should not preclude women from using HT when appropriate.

Breast Cancer :: Breast cancer awareness calls for cardiovascular awareness

Women who overcome breast cancer have every reason to celebrate. But a heart filled with joy may also be a heart damaged by life-saving cancer therapies, a growing body of research shows.

Prostate Cancer :: Prostate cancer increases hip fracture risk by eight times in 50 to 65 year-olds

Men who have prostate cancer are on average four times more likely to suffer a hip fracture, with rates rising to eight times in men aged 50 to 65, according to a study of more than 60,000 men published in the October issue of the urology journal BJU International. Danish researchers looked at 62,865 men aged 50 and over, with an average age of just under 67.

Prostate Cancer :: Surgery may offer best chance of long-term prostate cancer survival

A study from Switzerland suggests that men who have surgery for prostate cancer appear less likely to die of the disease within 10 years than men who choose other treatment options, especially if they are younger or have cancers with certain tumor cell characteristics, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Menopause :: Less than one-third of women aware of landmark hormone therapy study

Despite the huge publicity generated by a 2002 study on the potential dangers of hormone therapy for postmenopausal women, new research from the Stanford University School of Medicine found that only 29 percent of women surveyed knew about the study two years later.

Prostate Cancer :: First biomarker discovered that predicts prostate cancer outcome

Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery. The report on the B7-H3 molecule by Mayo Clinic Cancer Center appears today in Cancer Research.

Spirit India